VALN - Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline | Benzinga
Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million).
The company was awarded a tropical disease PRV in November 2023 following the FDA approval of Ixchiq, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to the mosquito-borne infection.
With this approval, Ixchiq became the world’s first licensed chikungunya vaccine.
Valneva will invest proceeds from the sale of the PRV into its R&D projects, including the co-development of its Phase 3 vaccine candidate against Lyme ...